JP2008513027A - フェニルアラニンアンモニアーリアーゼの改変体および化学的に修飾された改変体 - Google Patents

フェニルアラニンアンモニアーリアーゼの改変体および化学的に修飾された改変体 Download PDF

Info

Publication number
JP2008513027A
JP2008513027A JP2007532656A JP2007532656A JP2008513027A JP 2008513027 A JP2008513027 A JP 2008513027A JP 2007532656 A JP2007532656 A JP 2007532656A JP 2007532656 A JP2007532656 A JP 2007532656A JP 2008513027 A JP2008513027 A JP 2008513027A
Authority
JP
Japan
Prior art keywords
pal
protein
peg
activity
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007532656A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008513027A5 (enExample
Inventor
アレハンドラ ゲイムズ，
リン ワン，
ウーミ キム，
メアリー ストラウブ，
マリアン ジー． パッチ，
エミール カッキス，
ダン オッペンハイマー，
ポール エー． フィッツパトリック，
ロバート ヘフト，
レイモンド シー． スティーブンス，
Original Assignee
バイオマリン ファーマシューティカル インコーポレイテッド
ザ スクリプス リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオマリン ファーマシューティカル インコーポレイテッド, ザ スクリプス リサーチ インスティテュート filed Critical バイオマリン ファーマシューティカル インコーポレイテッド
Publication of JP2008513027A publication Critical patent/JP2008513027A/ja
Publication of JP2008513027A5 publication Critical patent/JP2008513027A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2007532656A 2004-09-17 2005-09-19 フェニルアラニンアンモニアーリアーゼの改変体および化学的に修飾された改変体 Pending JP2008513027A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61077004P 2004-09-17 2004-09-17
US65195005P 2005-02-09 2005-02-09
PCT/US2005/033895 WO2006034373A2 (en) 2004-09-17 2005-09-19 Variants and chemically-modified variants of phenylalanine ammonia-lyase

Publications (2)

Publication Number Publication Date
JP2008513027A true JP2008513027A (ja) 2008-05-01
JP2008513027A5 JP2008513027A5 (enExample) 2008-11-06

Family

ID=36090659

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007532656A Pending JP2008513027A (ja) 2004-09-17 2005-09-19 フェニルアラニンアンモニアーリアーゼの改変体および化学的に修飾された改変体

Country Status (6)

Country Link
US (1) US7553653B2 (enExample)
EP (1) EP1814984A2 (enExample)
JP (1) JP2008513027A (enExample)
AU (1) AU2005286763A1 (enExample)
CA (1) CA2580679A1 (enExample)
WO (1) WO2006034373A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016516428A (ja) * 2013-04-18 2016-06-09 コデクシス， インコーポレイテッド 操作されたフェニルアラニンアンモニアリアーゼポリペプチド
JP2021531749A (ja) * 2018-07-12 2021-11-25 コデクシス， インコーポレイテッド 操作されたフェニルアラニンアンモニアリアーゼポリペプチド

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1708690T3 (pl) 2003-11-17 2017-01-31 Biomarin Pharmaceutical Inc. Leczenie fenyloketonurii za pomocą BH4
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US8247370B2 (en) * 2006-12-04 2012-08-21 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
ES2906582T3 (es) 2007-04-11 2022-04-19 Biomarin Pharm Inc Métodos para administrar tetrahidrobiopterina, composiciones asociadas y métodos de medida
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
US7560263B2 (en) * 2007-08-17 2009-07-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
WO2010014225A2 (en) * 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
PT2405928T (pt) * 2009-03-11 2017-02-07 Promedior Inc Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
CA2755047C (en) * 2009-03-11 2018-12-04 Promedior, Inc. Treatment methods for autoimmune disorders
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
AU2010262847B2 (en) * 2009-06-17 2016-06-02 Promedior, Inc. SAP variants and their use
PL3025728T3 (pl) 2010-02-04 2018-12-31 Biomarin Pharmaceutical Inc. Sposób oczyszczania wariantów prokariotycznej amoniakoliazy fenyloalaninowej
EA025341B1 (ru) 2010-09-22 2016-12-30 Алиос Биофарма, Инк. Замещенные аналоги нуклеотидов
WO2013096680A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
JP6316810B2 (ja) 2012-07-26 2018-04-25 カサルカ ソシエダ アノニマCasaLuker S.A. カカオ（Ｔｈｅｏｂｒｏｍａｃａｃａｏ）からのフェノール化合物の生成を増大させる方法
DK3145536T3 (da) 2014-04-16 2022-01-03 Codexis Inc Modificeret tyrosinammoniaklyase
ES2881384T3 (es) 2015-05-13 2021-11-29 Synlogic Operating Co Inc Bacterias manipuladas para reducir la hiperfenilalaninemia
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CA3102968A1 (en) 2018-06-12 2019-12-19 Codexis, Inc. Engineered tyrosine ammonia lyase
AU2019397401A1 (en) 2018-12-14 2021-06-17 Codexis, Inc. Engineered tyrosine ammonia lyase
EP4045067A4 (en) * 2019-10-17 2023-11-15 Ikena Oncology, Inc. PEGYLATED KYNURENINASE ENZYMES AND THEIR USES FOR THE TREATMENT OF CANCER
KR20220137057A (ko) 2020-02-04 2022-10-11 코덱시스, 인코포레이티드 조작된 류신 데카르복실라제
CN115298308A (zh) * 2020-03-20 2022-11-04 同生运营公司 经工程化以减轻高苯丙氨酸血症的微生物
WO2022047262A1 (en) 2020-08-28 2022-03-03 Codexis, Inc. Engineered protease variants
CA3191900A1 (en) 2020-08-28 2022-03-03 Codexis, Inc. Engineered amylase variants
US12502421B2 (en) 2021-11-01 2025-12-23 Syntis Bio, Inc. Engineered leucine decarboxylases
CN118931888A (zh) * 2023-05-09 2024-11-12 重庆派金生物科技有限公司 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐
US20250108095A1 (en) * 2023-09-28 2025-04-03 Aperiam Bio, Inc. Degradation of toxins in vivo

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102712A1 (en) * 2000-07-24 2002-08-01 Pcbu Services, Inc. Phenylalanine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4562151A (en) * 1983-09-06 1985-12-31 Monsanto Company Stabilization of L-phenylalanine ammonia-lyase enzyme
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
DK75593D0 (enExample) * 1993-06-25 1993-06-25 Novo Nordisk As
US5981239A (en) * 1997-09-24 1999-11-09 Great Lakes Chemical Corp. Synthesis of optically active phenylalanine analogs using Rhodotorula graminis
US6451986B1 (en) * 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) * 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6686164B1 (en) * 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
CA2328614C (en) * 1999-02-12 2012-06-26 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
EP1280924A2 (en) * 2000-04-14 2003-02-05 University of South Carolina Research Foundation Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses
EP1476563B1 (en) * 2002-02-26 2008-09-17 E.I. Du Pont De Nemours And Company Method for the recombination of genetic elements
WO2004044169A2 (en) * 2002-11-14 2004-05-27 The Scripps Research Institute Crystalline form of fatty acid amine hydrolase (faah)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102712A1 (en) * 2000-07-24 2002-08-01 Pcbu Services, Inc. Phenylalanine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016516428A (ja) * 2013-04-18 2016-06-09 コデクシス， インコーポレイテッド 操作されたフェニルアラニンアンモニアリアーゼポリペプチド
JP2020185016A (ja) * 2013-04-18 2020-11-19 コデクシス， インコーポレイテッド 操作されたフェニルアラニンアンモニアリアーゼポリペプチド
JP7129715B2 (ja) 2013-04-18 2022-09-02 コデクシス， インコーポレイテッド 操作されたフェニルアラニンアンモニアリアーゼポリペプチド
JP2021531749A (ja) * 2018-07-12 2021-11-25 コデクシス， インコーポレイテッド 操作されたフェニルアラニンアンモニアリアーゼポリペプチド

Also Published As

Publication number Publication date
US7553653B2 (en) 2009-06-30
EP1814984A2 (en) 2007-08-08
WO2006034373A2 (en) 2006-03-30
AU2005286763A1 (en) 2006-03-30
WO2006034373A3 (en) 2006-11-02
CA2580679A1 (en) 2006-03-30
WO2006034373A9 (en) 2006-05-11
US20070048855A1 (en) 2007-03-01
WO2006034373A8 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
JP2008513027A (ja) フェニルアラニンアンモニアーリアーゼの改変体および化学的に修飾された改変体
JP5670183B2 (ja) 原核生物フェニルアラニンアンモニアリアーゼの組成物、及び、その組成物の使用方法
US20240035013A1 (en) Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
US7531341B1 (en) Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
BR112019016634A2 (pt) polipeptídeos, sequência de polinucleotídeos modificados por engenharia, vetor de expressão, célula hospedeira, métodos para produzir um polipeptídeo de fenilalanina amônia liase modificado por engenharia em uma célula hospedeira e para tratar e/ou prevenir os sintomas de fenilcetonúria em um indivíduo, composição, e, uso
JP2025143444A (ja) 操作されたロイシンデカルボキシラーゼ
US20230212239A1 (en) Inhibitors of cbl autoinhibition and related methods
US20240228983A1 (en) Modified Red Blood Cells and Uses Thereof For Treating Hyperuricemia and Gout
US7285408B2 (en) Crystalline form of an n231 mutant catalytic domain of ADAM33 and methods of use thereof
HK1135141B (en) Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using said compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111025